Tralokinumab companion diagnostic - Abbott
Latest Information Update: 29 Jun 2015
At a glance
- Originator Abbott Laboratories
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Asthma
Most Recent Events
- 13 May 2015 Phase-III clinical trials in Asthma (Diagnosis) in Asia, Canada, European Union and USA (unspecified route)